Bienvenue au réseau de diffusion sur l'arthrite Arthritis Research Centre of Canada Arthritis Consumer Experts

Men with low testosterone more likely to develop RA

Couple walking side by side in the sandA study in the Swedish Malmo Preventive Medicine Program (MPMP) found that men with low testosterone were more likely to develop rheumatoid arthritis. The study participants included 33,000 people born between 1921 and 1949. As part of the study, the participants underwent a number of tests, filled out questionnaires, and provided blood samples.

In the study, low testosterone levels are observed in both men and women with rheumatoid arthritis (RA). Further study is required to determine whether low testosterone levels are to blame for the onset of RA, or it is RA that drops the levels of testosterone. Continue reading

New robotic horse for arthritis

A team of student engineers from William Marsh Rice University, a private research university located in Houston, Texas, has developed a robotic horse that may help patients with arthritis. Based on the premise of hippotherapy, also known as equine-assisted therapy, the horse simulator is a robotic horse that can be ridden indoors anytime.

Hippotherapy relies on horses to improve the symptoms of patients with neurological or physical illnesses like autism, cerebral palsy, and arthritis. The rhythmic, swinging motion passes through the entire body and is thought to enhance balance, coordination and motor development. This form of treatment is prohibitive because of its cost and accessibility. Physical therapy sessions with a horse can cost upwards of $150 an hour. Continue reading

Explore the role of exercise on physical and brain health

Picture of people walking on a sidewalkA free workshop by Aging, Mobility, and Cognitive Neuroscience Lab

Explore the role of exercise on physical and brain health with professional experts Drs. Steven Blair, Kirk Erickson, and Brian Saelens. The doctors will be sharing their research on the physical and cognitive health benefits of physical activity in today’s society.

Space is limited so please register by April 29, 2016!

Date: Friday, May 6, 2016
Time: 3pm-5pm
Location: University Centre (UBC), 6331 Crescent Road, Sage East (Main Level)
*Registration opens at 2:30pm. Light refreshments will be provided.

About the speakers
Continue reading

Have you signed up yet?

Have you recently been recommended to START or SWITCH biologic medications for rheumatoid arthritis?

SuPER study bannerWe are looking for people with rheumatoid arthritis across Canada to test a new online tool that helps to make decisions about using biologic medications.

If you have been recommended to consider STARTING or SWITCHING biologics, we invite you to participate in this study.

You may be eligible if you:

  1. Have rheumatoid arthritis
  2. See a rheumatologist
  3. You are considering or reconsidering starting or switching biologics
  4. Have a valid email and internet access

This study can be completed from home or anywhere with internet access. Any information you provide will be completely confidential. An honorarium will be provided for your time.

If you would like more information, please contact Jasmina Memetovic, Research Coordinator by phone at 604-207-4007, toll free 1-877-871-4575, or email jmemetovic@arthritisresearch.ca.

Demande de rétroaction de patients sur un produit biologique ultérieur de l’innovateur étanercept…

Stickman with megaphone calling for patient input…dans le traitement de la polyarthrite rhumatoïde et de la spondylarthrite ankylosante.

Souffrez-vous de polyarthrite rhumatoïde ou de spondylarthrite ankylosante ou prodiguez-vous des soins à quelqu’un qui en souffre ? Vos commentaires seraient précieux.

Santé Canada définit le produit biologique ultérieur (PBU) comme étant un produit biologique qui présente une similarité établie avec un médicament biologique innovateur (tel que Enbrel®) et qui a fait son entrée sur le marché après l’innovateur auquel il se réfère.

Contrairement aux médicaments plus communs à petites molécules, les médicaments biologiques présentent généralement une complexité moléculaire élevée et sont sensibles aux modifications dans les pratiques de fabrication. Les PBU ne sont pas identiques à leurs produits innovateurs parce que leurs caractéristiques chimiques ne peuvent être facilement copiées. Toutefois, les PBU possèdent des profils uniques en matière d’efficacité, d’immunogénicité et d’innocuité qui diffèrent de leurs produits innovateurs respectifs. Continue reading

Call for patient input on SEB etanercept for RA and AS

Stickman with megaphone calling for patient input

Call for patient input on SEB etanercept for rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Do you have RA or AS or care for someone who does? We need your valuable input.

Health Canada defines subsequent entry biologics (SEBs) as biologic medicines that are similar to, and would enter the market after an approved innovator biologic (such as Enbrel®).

Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and are sensitive to changes in manufacturing practices. SEBs are not identical to their innovator products because their chemical characteristics cannot be precisely duplicated during the manufacturing process. Therefore, SEBs may have unique efficacy, immunogenicity, and safety profiles that are different from their innovator products.

The Common Drug Review (CDR) is currently welcoming patients and their caregivers to provide input to patient organizations on the manufacturer’s submission for SEB etanercept for the treatment of rheumatoid arthritis or ankylosing spondylitis. The innovator biologic, or reference product, is etanercept (Enbrel®). Continue reading